Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Gained about 20% over 21 sessions and surged 17.9% after the latest GSK licensing deal delivered $110 million upfront and up to $1.295 billion in potential payments. Positive Phase III data and recent Chinese approvals add clinical and regulatory support.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Weak Cash Flow ⢠Investment Concentration HCM's strong reported profitability, liquidity, and lower leverage are offset by negative operating/free cash flow, investment concentration, and negative retained earnings, warranting caution on earnings quality.
Price Behavior
Key Price Behavior Insights: ⢠Positive monthly trend ⢠Profit-taking pressure ⢠Key breakout test Support Level: $13.40â$13.50; $12.80â$13.00 Resistance Level: $13.80â$14.11 HCM remains bullish over the last month but is consolidating below $13.80â$14.11 resistance, with a break below $13.40â$13.50 risking a pullback toward $12.80â$13.00.
Sentiment & News
Key News Insights: ⢠GSK Licensing Deal ⢠ATLED Approval ⢠Positive Trial Data Hutchmed's GSK licensing deal, ATLED approval, and positive SANOVO data strengthen its oncology pipeline and near-term growth outlook.
AI Summary
HUTCHMED's GSK deal and expanding oncology approvals strengthen its long-term pipeline value and liquidity runway, but investors should treat HCM as a cash-burning, execution-dependent biotech until product launches and milestones translate into sustained operating cash flow; monitor China uptake and a breakout above $14.11 for confirmation.
Description
HUTCHMED (China) Limited is a Hong Kongâbased biopharmaceutical company that discovers, develops and commercializes targeted small molecules and immunotherapies primarily for oncology and selected immunological conditions. Its pipeline comprises multiple classes of targeted agents and epigenetic therapies addressing a range of solid tumors and hematologic malignancies, and the company operates through Oncology/Immunology and Other Ventures segments. HUTCHMED maintains collaboration agreements with several global and Chinese biopharma firms and was incorporated in 2000 (name changed from Hutchison China MediTech Limited in 2021).
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 3 | Sep 10 | HCM | HUTCHMED (China) Limited | Gained about 20% over 21 sessions and surged 17.9% after the latest GSK licensing deal delivered $110 million upfront and up to $1.295 billion in potential payments. Positive Phase III data and recent Chinese approvals add clinical and regulatory support. | Closed | -7.0% |